Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602193 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
A Phase 2 study of Parkinson Disease, sponsored by Denali Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06602193: Recruiting Phase 2 study of Parkinson Disease, sponsored by Denali Therapeutics.
NCT06602193 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Denali Therapeutics. The registered enrollment target is 50 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602193, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Denali Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Conditions Studied
Interventions
- DRUG BIIB122 225 mg
- OTHER BIIB122-Matching Placebo
Study Locations (20)
Other
- Technische Universität Dresden - Dresden
- University of Lübeck - Lübeck
- University Hospital Tübingen - Tübingen
- Rabin Medical Center - Petah Tikva
- Movement Disorders Institute, Sheba Medical Center - Ramat Gan
- Tel Aviv Medical Center - Tel Aviv
- Hospital Clinic de Barcelona - Barcelona
- Hospital Universitari General de Catalunya - Barcelona
- Hospital Universitari Vall d'Hebron - Barcelona
- Hospital Universitario Donostia - Donostia / San Sebastian
- Universitary Hospital La Princesa - Madrid
- IDIVAL/University Hospital Marques de Valdecilla - Santander
- Hospital Universitario Virgen del Rocio - Seville
California
- Cedars-Sinai Department of Neurology - Los Angeles
- University of California San Francisco - San Francisco
Washington
- Evergreen Health Laboratory - Kirkland
- Inland Northwest Research - Spokane
Florida
- Parkinson's Disease and Movement Disorders Center - Boca Raton
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 2 |
What NCT06602193 shows while recruiting
NCT06602193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which BIIB122 225 mg is the first listed.
NCT06602193 names 20 study sites across 6 states, led by Other, California, Washington.
Frequently Asked Questions
What is clinical trial NCT06602193 about?
NCT06602193 is a clinical study titled "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)". This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in indiv...
What is the current status of trial NCT06602193?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-10-24. Estimated completion is 2028-02-28.
What conditions does trial NCT06602193 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06602193?
The interventions under investigation include: BIIB122 225 mg (DRUG), BIIB122-Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT06602193?
This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06602193 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06602193's enrollment target sits among peer trials
50 155th of 297 higher than 135 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI